CRVO Nasdaq Pharmaceutical Preparations Financials FY2016βFY2025
CervoMed Inc. had $4.0M of revenue in fiscal 2025, down 58.9% on the year before.
Last close Β· Oct 23, 2026
$2.31
3.1%Hi! I read CervoMed Inc.βs latest annual report (fiscal 2025). Here is what stands out:
Good So-so Weak
Are sales growing?
β58.9%
No. Sales fell 58.9% last year.
Does it make a profit?
β673.1%
No. It lost money last year.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Is it selling more, and how much does it keep?
KIRA Β· CervoMed Inc. had $4.0M of revenue in fiscal 2025, down 58.9% on the year before. Its operating margin was β706.2%, down 519.0Β pts: of every 100 in sales, about β706 is left after running the business.
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
Revenue
Margins, % of revenue
Margins, % of revenue
KIRA Β· CervoMed Inc. lost $27.0M in fiscal 2025.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
Net income
Diluted EPS
Diluted EPS
How much cash comes in, and where does it go?
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
Cash from operations vs capital spending
Cash from operations vs capital spending
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
Diluted shares outstanding (annual)
KIRA Β· In the last 12 months, insiders bought $3.5M of shares on the open market and sold none.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$3.5M
4 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Jun 11, 2026 | Joshua S BogerDirector, 10% owner | Bought | 955,414 | $3.14 | $3.0M | Form 4 |
| Nov 18, 2025 | Matthew WintonChief Commercial and Business | Bought | 1,500 | $7.95 | $0.0M | Form 4 |
| Nov 18, 2025 | William Robert ElderCFO, GC & Secretary | Bought | 2,500 | $8.32 | $0.0M | Form 4 |
| Nov 17, 2025 | John J AlamCEO & President, Director, 10% owner | Bought | 21,600 | $8.46 | $0.2M | Form 4 |
| Nov 17, 2025 | Matthew WintonChief Commercial and Business | Bought | 3,500 | $8.43 | $0.0M | Form 4 |
| Nov 17, 2025 | William Robert ElderCFO, GC & Secretary | Bought | 1,000 | $8.45 | $0.0M | Form 4 |
| Nov 14, 2025 | John J AlamCEO & President, Director, 10% owner | Bought | 3,400 | $7.56 | $0.0M | Form 4 |
| Nov 14, 2025 | Matthew WintonChief Commercial and Business | Bought | 10,000 | $7.57 | $0.1M | Form 4 |
| Nov 13, 2025 | John J AlamCEO & President, Director, 10% owner | Bought | 4,447 | $7.51 | $0.0M | Form 4 |
| Nov 12, 2025 | John J AlamCEO & President, Director, 10% owner | Bought | 5,553 | $7.35 | $0.0M | Form 4 |
| Nov 12, 2025 | William Robert ElderCFO, GC & Secretary | Bought | 3,500 | $7.44 | $0.0M | Form 4 |
Can it carry its debts, and how well does it use its money?
Cash, debt and the ratios that show how comfortably CervoMed Inc. can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $37.3M | $16.5M | $7.8M | $38.9M | $20.9M |
| Interest coverage | β | β5,792.5x | β | β | β |
| Current ratio | 12.9x | β | β | 11.1x | 4.9x |
| Quick ratio | 12.9x | β | β | 11.1x | 4.9x |
| Total assets | $37.8M | $4.2M | $10.0M | $43.1M | $22.9M |
| Total liabilities | $2.9M | $13.2M | $2.6M | $3.9M | $4.7M |
| Shareholders' equity | $34.9M | β$33.3M | $7.4M | $39.2M | $18.2M |
| Net debt (β = net cash) | β | β | β | β | β |
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β | β | β | β |
| F-score | β / 3 | β / 6 | β / 6 | β / 5 | β / 5 | β / 5 | β / 4 | β / 5 | β / 5 | β / 6 |
| Accruals ratio | β41.6% | 50.3% | β34.3% | β9.2% | β2.4% | β29.3% | β15.4% | 74.7% | 0.9% | β10.7% |
| Altman Z'' | β18.19 | β4.31 | β12.06 | β6.79 | β3.52 | 2.99 | β | β | 8.38 | β12.90 |
Every number, year by year.
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | β | β | β | β | β | β | $0.0M | $7.1M | $9.7M | $4.0M |
| Research and development | $7.3M | $5.1M | $5.8M | $6.6M | $9.4M | $8.5M | $1.3M | $8.4M | $18.8M | $21.8M |
| Operating income | β$18.4M | β$11.3M | β$19.0M | β$11.6M | β$16.0M | β$24.7M | β$3.5M | β$7.8M | β$18.2M | β$28.3M |
| Interest expense | $0.0M | $0.1M | $0.0M | β | β | β | $0.0M | $0.0M | β | β |
| Pretax income | β$18.4M | β$2.4M | β$18.8M | β$11.5M | β$15.9M | β$24.5M | β$15.6M | β | β | β |
| Income tax | β$0.4M | β$1.1M | β$0.4M | $0.3M | β$1.7M | β$0.4M | $0.0M | β | β | $0.0M |
| Net income | β$18.0M | β$1.4M | β$18.4M | β$11.8M | β$14.2M | β$24.1M | β$5.8M | β$2.2M | β$16.3M | β$27.0M |
| Net income to common | β$18.0M | β$2.6M | β$26.6M | β$11.8M | β$16.1M | β$24.1M | β | β | β | β |
| Diluted EPS | β$1.76 | β$29.11 | $3,242,301.00 | $6,706,509.00 | $53,831,973.00 | $1,946,859.00 | $2,038,891.00 | β | β | β |
| Diluted shares | 0.01B | 0.00B | 0.00B | β | β | β | β | β | β | β |
| Cash flow | ||||||||||
| Cash from operations | β$10.8M | β$12.3M | β$10.8M | β$9.9M | β$13.6M | β$14.5M | β$2.6M | β$7.4M | β$16.5M | β$23.5M |
| Capital expenditure | $0.0M | $0.4M | β | β | β | β | β | β | β | β |
| Free cash flow | β$10.8M | β$12.8M | β | β | β | β | β | β | β | β |
| Depreciation and amortization | $0.0M | $0.1M | $0.1M | $0.1M | $0.1M | $0.1M | $0.0M | β | β | β |
| Stock-based compensation | $1.4M | $1.2M | $1.2M | $0.5M | $0.7M | $0.9M | $0.3M | $0.4M | $1.4M | $1.4M |
| Balance sheet | ||||||||||
| Cash and short-term investments | $1.6M | $8.9M | $8.0M | $14.2M | $18.5M | $37.3M | $16.5M | $7.8M | $38.9M | $20.9M |
| Current assets | $1.6M | $9.7M | $8.9M | $14.6M | $18.8M | $37.8M | $4.2M | $10.0M | $43.1M | $22.9M |
| Current liabilities | $4.4M | $2.7M | $0.8M | $1.7M | $2.4M | $2.9M | β | β | $3.9M | $4.7M |
| Property and equipment, net | $0.1M | $0.5M | $0.4M | $0.3M | $0.1M | $0.0M | β | β | β | β |
| Goodwill | $6.9M | $6.9M | $0.0M | β | β | β | β | β | β | β |
| Intangible assets | $8.6M | β | β | β | β | β | β | β | β | β |
| Total assets | $17.5M | $26.1M | $18.2M | $24.1M | $27.7M | $37.8M | $4.2M | $10.0M | $43.1M | $22.9M |
| Total liabilities | $8.3M | $4.9M | $2.6M | $4.0M | $2.9M | $2.9M | $13.2M | $2.6M | $3.9M | $4.7M |
| Preferred stock | β | β | β | β | β | β | β | $0.0M | β | β |
| Shareholders' equity | $9.2M | $21.2M | $15.6M | $20.1M | $24.8M | $34.9M | β$33.3M | $7.4M | $39.2M | $18.2M |
| Margins | ||||||||||
| Operating margin | β | β | β | β | β | β | β | β109.3% | β187.2% | β706.2% |
| Net margin | β | β | β | β | β | β | β | β30.4% | β167.3% | β673.1% |
| Returns | ||||||||||
| Return on capital employed | β140.8% | β48.4% | β109.0% | β51.6% | β63.2% | β70.7% | β | β | β46.5% | β155.3% |
| Return on equity | β196.4% | β9.0% | β99.7% | β66.0% | β63.1% | β80.7% | β713.6% | β | β69.9% | β93.9% |
| Return on assets | β103.2% | β6.3% | β82.8% | β55.8% | β54.7% | β73.5% | β27.6% | β30.7% | β61.4% | β81.8% |
| Return on tangible equity | β | β18.3% | β170.5% | β58.6% | β65.0% | β69.0% | β | β29.4% | β41.6% | β148.0% |
| Growth | ||||||||||
| Revenue growth | β | β | β | β | β | β | β | β | 36.3% | β58.9% |
| EPS growth | β | β | β | 106.8% | 702.7% | β96.4% | 4.7% | β | β | β |
| Share count change | β | β91.7% | 282.3% | β | β | β | β | β | β | β |
| Financial health | ||||||||||
| Interest coverage | β496.5x | β113.5x | β6,319.6x | β | β | β | β5,792.5x | β | β | β |
| Current ratio | 0.4x | 3.6x | 11.1x | 8.5x | 7.7x | 12.9x | β | β | 11.1x | 4.9x |
| Quick ratio | 0.4x | 3.6x | 11.1x | 8.5x | 7.7x | 12.9x | β | β | 11.1x | 4.9x |
| Capital allocation | ||||||||||
| Stock comp / revenue | β | β | β | β | β | β | β | 5.7% | 14.4% | 36.2% |
| Quality scores | ||||||||||
| Altman Z'' | β18.2 | β4.3 | β12.1 | β6.8 | β3.5 | 3.0 | β | β | 8.4 | β12.9 |
| Accruals ratio | β41.6% | 50.3% | β34.3% | β9.2% | β2.4% | β29.3% | β15.4% | 74.7% | 0.9% | β10.7% |
Source: SEC EDGAR XBRL filings (CIK 0001053691). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.
